[go: up one dir, main page]

MX2013004190A - Composiciones y metodos para el tratamiento de la hipertension pulmonar. - Google Patents

Composiciones y metodos para el tratamiento de la hipertension pulmonar.

Info

Publication number
MX2013004190A
MX2013004190A MX2013004190A MX2013004190A MX2013004190A MX 2013004190 A MX2013004190 A MX 2013004190A MX 2013004190 A MX2013004190 A MX 2013004190A MX 2013004190 A MX2013004190 A MX 2013004190A MX 2013004190 A MX2013004190 A MX 2013004190A
Authority
MX
Mexico
Prior art keywords
methods
pulmonary hypertension
compositions
treating pulmonary
formulations
Prior art date
Application number
MX2013004190A
Other languages
English (en)
Other versions
MX346730B (es
Inventor
Luiz Belardinelli
Hunter Campbell Gillies
Faquan Liang
John Shryock
Suya Yang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45939010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013004190(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2013004190A publication Critical patent/MX2013004190A/es
Publication of MX346730B publication Critical patent/MX346730B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan formulaciones que comprenden cantidades terapéuticamente efectivas de ambrisentán o una sal farmacéuticamente aceptable del mismo y tadalafil o una sal farmacéuticamente aceptable del mismo y los métodos para tratar y/o prevenir la hipertensión pulmonar mediante la administración de las formulaciones.
MX2013004190A 2010-10-15 2011-10-14 Composiciones y metodos para el tratamiento de la hipertension pulmonar. MX346730B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39352910P 2010-10-15 2010-10-15
US201161490454P 2011-05-26 2011-05-26
US201161497475P 2011-06-15 2011-06-15
PCT/US2011/056404 WO2012051559A2 (en) 2010-10-15 2011-10-14 Compositions and methods of treating pulmonary hypertension

Publications (2)

Publication Number Publication Date
MX2013004190A true MX2013004190A (es) 2013-07-29
MX346730B MX346730B (es) 2017-03-30

Family

ID=45939010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004190A MX346730B (es) 2010-10-15 2011-10-14 Composiciones y metodos para el tratamiento de la hipertension pulmonar.

Country Status (26)

Country Link
US (3) US20120269898A1 (es)
EP (2) EP3106163A1 (es)
JP (2) JP5806320B2 (es)
KR (2) KR20150002876A (es)
CN (1) CN103458690B (es)
AR (1) AR083422A1 (es)
AU (2) AU2011315891B2 (es)
BR (1) BR112013008983A2 (es)
CA (1) CA2814518C (es)
CY (1) CY1119007T1 (es)
DK (1) DK2637664T3 (es)
EA (2) EA026074B1 (es)
ES (1) ES2627944T3 (es)
HR (1) HRP20170848T1 (es)
HU (1) HUE033346T2 (es)
LT (1) LT2637664T (es)
MX (1) MX346730B (es)
NZ (2) NZ610012A (es)
PL (1) PL2637664T3 (es)
PT (1) PT2637664T (es)
RS (1) RS56135B1 (es)
SI (1) SI2637664T1 (es)
SM (1) SMT201700297T1 (es)
TW (1) TWI542580B (es)
WO (1) WO2012051559A2 (es)
ZA (1) ZA201302746B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512414A (ja) 2006-12-12 2010-04-22 ギリード・コロラド・インコーポレーテッド 肺高血圧を処置するための組成物
US20120269898A1 (en) 2010-10-15 2012-10-25 Luiz Belardinelli Compositions and methods of treating pulmonary hypertension
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014174529A2 (en) * 2013-04-23 2014-10-30 Hetero Research Foundation Polymorphs of avanafil
US20150125546A1 (en) * 2013-11-06 2015-05-07 Gilead Sciences, Inc. Combination therapy for treating pulmonary hypertension
CN105581990A (zh) * 2014-08-27 2016-05-18 人福医药集团股份公司 安立生坦片剂及其制备方法
CN107847462B (zh) * 2015-03-13 2021-08-10 美国印第安纳大学研究和技术公司 靶向cGMP相关的磷酸二酯酶以减少囊性肾病的囊肿形成和相关的材料与方法
US10722558B2 (en) * 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
KR102543227B1 (ko) * 2016-10-27 2023-06-13 풀모킨 인코포레이티드 폐고혈압을 치료하기 위한 병용 요법
WO2019010445A1 (en) * 2017-07-07 2019-01-10 The Regents Of The University Of Colorado, A Body Corporate COMPOSITIONS AND METHOD FOR THE TREATMENT OF PULMONARY HYPERTENSION
WO2019130052A1 (en) 2017-12-26 2019-07-04 Ftf Pharma Private Limited Liquid oral formulations for pde v inhibitors
CN109406688A (zh) * 2018-09-28 2019-03-01 中国食品药品检定研究院 用于检测产品中违禁药品的标准样品
ES2994089T3 (en) * 2019-11-29 2025-01-17 Actelion Pharmaceuticals Ltd Initial triple combination therapy with macitentan, tadalafil, and selexipag for treating pulmonary arterial hypertension
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
CN112826944B (zh) * 2021-01-29 2023-08-15 台州职业技术学院 一种安立生坦包合物及其制备方法
EP4456897A4 (en) 2021-12-31 2025-12-10 Tenax Therapeutics Inc ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
EP4684777A1 (en) 2024-07-24 2026-01-28 Adalvo Limited A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
CA2309332C (en) 1997-11-12 2002-12-03 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
US20060292213A1 (en) 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
TW200621261A (en) * 2004-08-26 2006-07-01 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI
WO2008073927A1 (en) * 2006-12-12 2008-06-19 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
JP2010512414A (ja) * 2006-12-12 2010-04-22 ギリード・コロラド・インコーポレーテッド 肺高血圧を処置するための組成物
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
US20120269898A1 (en) 2010-10-15 2012-10-25 Luiz Belardinelli Compositions and methods of treating pulmonary hypertension

Also Published As

Publication number Publication date
AU2016204638B2 (en) 2018-06-07
US9549926B2 (en) 2017-01-24
TWI542580B (zh) 2016-07-21
EA026074B1 (ru) 2017-02-28
CN103458690B (zh) 2016-03-16
JP2014506870A (ja) 2014-03-20
ZA201302746B (en) 2014-06-25
EP3106163A1 (en) 2016-12-21
TW201219372A (en) 2012-05-16
US20160346280A1 (en) 2016-12-01
EA201390428A1 (ru) 2014-02-28
NZ610012A (en) 2015-05-29
JP5806320B2 (ja) 2015-11-10
NZ707213A (en) 2016-12-23
WO2012051559A2 (en) 2012-04-19
SMT201700297T1 (it) 2017-07-18
PT2637664T (pt) 2017-06-22
US20120269898A1 (en) 2012-10-25
ES2627944T3 (es) 2017-08-01
JP2015178528A (ja) 2015-10-08
KR20130069855A (ko) 2013-06-26
RS56135B1 (sr) 2017-10-31
AR083422A1 (es) 2013-02-21
EP2637664B1 (en) 2017-03-29
PL2637664T3 (pl) 2017-09-29
DK2637664T3 (en) 2017-06-19
HUE033346T2 (en) 2017-11-28
CA2814518A1 (en) 2012-04-19
AU2011315891B2 (en) 2015-08-13
BR112013008983A2 (pt) 2016-07-05
EP2637664A4 (en) 2014-09-10
MX346730B (es) 2017-03-30
CN103458690A (zh) 2013-12-18
LT2637664T (lt) 2017-11-10
SI2637664T1 (sl) 2017-07-31
WO2012051559A3 (en) 2013-10-17
EA201691759A1 (ru) 2017-05-31
CY1119007T1 (el) 2018-01-10
AU2011315891A1 (en) 2013-05-23
CA2814518C (en) 2016-09-20
US20140275098A1 (en) 2014-09-18
EP2637664A2 (en) 2013-09-18
AU2016204638A1 (en) 2016-08-04
HRP20170848T1 (hr) 2017-08-25
KR20150002876A (ko) 2015-01-07

Similar Documents

Publication Publication Date Title
MX2013004190A (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
MX338327B (es) Inhibidores de cdk.
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
UA115320C2 (uk) Інгібітори кінази
MY187718A (en) Pharmaceutical formulations
MX348823B (es) Formulaciones estables de linaclotida.
MY183974A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
PH12013501574A1 (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
IN2015DN01119A (es)
AU2012280198A8 (en) Darunavir combination formulations
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX341976B (es) Formulaciones de darunavir.
IN2014DN09347A (es)
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
WO2013074871A3 (en) Humanin analogs
MX2011011899A (es) Metodo para reducir los niveles proteicos ubiquitinados.
WO2011039675A3 (en) Latrepirdine transdermal therapeutic dosage forms
WO2011125006A3 (en) Sultam compounds

Legal Events

Date Code Title Description
FG Grant or registration